Since the introduction of docetaxel, research has focused on various approaches to
overcome treatment limitations and improve outcome. This review discusses the
pharmacological attempts at treatment optimisation, which include reducing interindividual
pharmacokinetic and pharmacodynamic variability, optimising schedule, route of
administration, reversing drug resistance and the development of structurally related second-
generation taxanes.